**Summary of IP Group PLCs Half-Yearly Results 2025**
IP Group PLC, a UK-based investor in breakthrough science and innovation companies, announced its financial results for the six months ended 30 June 2025 (HY25). The report highlights the companys progress in portfolio development, financial performance, and strategic initiatives.
**Key Highlights**
1. **Portfolio Developments**
**Hinge Health IPO** Hinge Healths successful IPO on the NYSE, with shares trading up 63% post-IPO, valued IP Groups holding at £39.1m.
**Oxford Nanopore Performance** Oxford Nanopore exceeded guidance with £105.6m in H1 revenues and lower EBITDA losses.
**Capital Raised** Portfolio companies raised £372m in total capital (HY24: £380m
FY24£784m).
**Investments** IP Group invested £36m across 21 companies, maintaining capital discipline.
**Notable Fundraisings** Accelercomm ($15m), Lumai ($10m), Tado (€30m from Panasonic), Vytal (€14.2m), and Mixergy (£12m).
2. **Financial Performance**
**Cash Proceeds** Total cash proceeds from exits were £30.3m, a 9x increase from HY24.
**Net Asset Value (NAV)** NAV per share was 96.2p, with a closing NAV of £883.1m. Public company gains (Oxford Nanopore and Hinge Health) and share buybacks offset losses from Oxa and Artios, as well as FX translation losses.
**NAV per Share Update** As of 12 September 2025, NAV per share was approximately 100p.
**Loss for the Period** Reported a loss of £43.0m (HY24: £109.9m
FY24£207.0m).
3. **Funds Under Management**
**Third-Party Funds** Raised £24m in third-party funds (Parkwalk), with total third-party AUM at £663m (HY24: £637m
FY24£678m).
**New Fund Launch** Parkwalk and Northern Gritstone launched the Northern Universities Venture Fund.
4. **Financial Strength and Discipline**
**Cash Position** Gross cash increased by 47% to £237.3m compared to HY24.
**Share Buyback** Completed £25m of share buybacks in H1, with a further £20m extension launched. Retired 6% of share capital in the period and 14% to date.
**Overheads** Net overheads run rate in line with guidance, with a 12% reduction for the period.
5. **Post-Period Updates**
**Fair Value Increase** Fair value of listed company holdings increased by £32m since 30 June, including a £23m increase in Oxford Nanopore.
**Istesso Data** Istesso reported groundbreaking data demonstrating tissue repair in fibrotic, autoinflammatory, and autoimmune conditions.
6. **Strategic Focus**
**Exits Target** Confident of delivering over £250m of exits between 2025 and 2027.
**Mansion House Accord** Well-positioned to benefit from reforms as major pension providers respond to the Mansion House Accord.
7. **CEOs Commentary**
Greg Smith highlighted strong progress, including the Hinge Health IPO and Oxford Nanopore gains, underscoring the portfolios resilience. He emphasized confidence in delivering significant exits and benefiting from fiscal reforms and rising demand for high-growth innovation.
**Conclusion**
IP Group PLC demonstrated robust progress in HY25, with significant portfolio developments, improved financial metrics, and strategic initiatives positioning the company for continued growth and value creation. The company remains focused on delivering exits, increasing funds under management, and maintaining financial discipline while investing for growth.
| Metric | HY 2025 | HY 2024 | FY 2024 | Change HY 2025 vs HY 2024 | Change HY 2025 vs FY 2024 |
|---|---|---|---|---|---|
| Net Asset Value (NAV) | 883.1 | 1,072.2 | 952.5 | -17.6% | -7.3% |
| NAV per share (pence) | 96.2 | 104.7 | 97.7 | -8.1% | -1.5% |
| Loss for the period | (43.0) | (109.9) | (207.0) | 60.9% | 79.2% |
| Total portfolio | 799.9 | 1,111.0 | 837.4 | -28.0% | -4.5% |
| Gross cash and deposits | 237.3 | 161.3 | 285.6 | 47.1% | -16.9% |
| Cash proceeds | 30.3 | 3.4 | 183.4 | 791.2% | -83.5% |
| Portfolio investment | 35.7 | 49.1 | 63.0 | -27.3% | -43.3% |
| Borrowings | 126.0 | 132.1 | 129.1 | -4.6% | -2.4% |